Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11.

Bonora E, Frias JP, Tinahones FJ, Van J, Malik RE, Yu Z, Mody R, Bethel A, Kwan AYM, Cox DA

Diabetes, obesity & metabolism29 Jun 2021Cited by 52 (Europe PMC)

PMID34189841PMCIDPMC8518850DOI10.1111/dom.14465PepBankPUB-34189841

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type II diabetes, dulaglutide 1.5 mg reduced weight from baseline at 36 weeks.
In plain wordsIn patients with diabetes, weight decreased from baseline with dulaglutide 1.5 mg at 36 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWeight change at 36 weeks
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
1.5 mg once weekly · 36 weeksAs given in this study (human).
Measurements
Weight change
−3.1 kg
1.5 mg
Source sentences
Summary
At 36 weeks, dulaglutide 3.0 and 4.5 mg were superior to 1.5 mg for weight change from baseline (1.5 mg, -3.1 kg; 3.0 mg, -4.0 kg [P = .001]; 4.5 mg, -4.7 kg [P < .001]).
1 context sentence(design, population, supporting numbers)
Summary · context
To evaluate the impact of dulaglutide 3.0 and 4.5 mg versus 1.5 mg on body weight in patients with type 2 diabetes (T2D) based on exploratory analyses of the AWARD-11 trial.Materials and methodsPatients were randomized to once-weekly dulaglutide 1.5 (n = 612), 3.0 (n = 616) or 4.5 mg (n = 614) for 52 weeks.
Report a problemFND-3418984101
02HumanRandomized controlled trialEfficacy outcome
In patients with type II diabetes, dulaglutide 3.0 mg reduced weight more than 1.5 mg at 36 weeks.
In plain wordsIn patients with diabetes, dulaglutide 3.0 mg reduced weight more than 1.5 mg at 36 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWeight change at 36 weeks
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg once weekly · 36 weeksAs given in this study (human).
Measurements
Weight change
−4 kg
3.0 mg
Weight change
−3.1 kg
1.5 mg
Source sentences
Summary
At 36 weeks, dulaglutide 3.0 and 4.5 mg were superior to 1.5 mg for weight change from baseline (1.5 mg, -3.1 kg; 3.0 mg, -4.0 kg [P = .001]; 4.5 mg, -4.7 kg [P < .001]).
1 context sentence(design, population, supporting numbers)
Summary · context
To evaluate the impact of dulaglutide 3.0 and 4.5 mg versus 1.5 mg on body weight in patients with type 2 diabetes (T2D) based on exploratory analyses of the AWARD-11 trial.Materials and methodsPatients were randomized to once-weekly dulaglutide 1.5 (n = 612), 3.0 (n = 616) or 4.5 mg (n = 614) for 52 weeks.
Report a problemFND-3418984102
03HumanRandomized controlled trialEfficacy outcome
In patients with type II diabetes, dulaglutide 4.5 mg reduced weight more than 1.5 mg at 36 weeks.
In plain wordsIn patients with diabetes, dulaglutide 4.5 mg reduced weight more than 1.5 mg at 36 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWeight change at 36 weeks
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
4.5 mg once weekly · 36 weeksAs given in this study (human).
Measurements
Weight change
−4.7 kg
4.5 mg
Weight change
−3.1 kg
1.5 mg
Source sentences
Summary
At 36 weeks, dulaglutide 3.0 and 4.5 mg were superior to 1.5 mg for weight change from baseline (1.5 mg, -3.1 kg; 3.0 mg, -4.0 kg [P = .001]; 4.5 mg, -4.7 kg [P < .001]).
1 context sentence(design, population, supporting numbers)
Summary · context
To evaluate the impact of dulaglutide 3.0 and 4.5 mg versus 1.5 mg on body weight in patients with type 2 diabetes (T2D) based on exploratory analyses of the AWARD-11 trial.Materials and methodsPatients were randomized to once-weekly dulaglutide 1.5 (n = 612), 3.0 (n = 616) or 4.5 mg (n = 614) for 52 weeks.
Report a problemFND-3418984103
04HumanRandomized controlled trialEfficacy outcome
In each baseline BMI and HbA1c subgroup, dulaglutide 3.0 mg showed numerically greater weight reduction than 1.5 mg.
In plain wordsIn each starting BMI and HbA1c subgroup, dulaglutide 3.0 mg showed numerically greater weight loss than 1.5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWeight reduction across baseline BMI and HbA1c subgroups
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg once weeklyAs given in this study (human).
Source sentences
Summary
Higher dulaglutide doses were associated with numerically greater weight reduction compared with 1.5 mg in each baseline BMI and HbA1c subgroup.
1 context sentence(design, population, supporting numbers)
Summary · context
To evaluate the impact of dulaglutide 3.0 and 4.5 mg versus 1.5 mg on body weight in patients with type 2 diabetes (T2D) based on exploratory analyses of the AWARD-11 trial.Materials and methodsPatients were randomized to once-weekly dulaglutide 1.5 (n = 612), 3.0 (n = 616) or 4.5 mg (n = 614) for 52 weeks.
Report a problemFND-3418984104
05HumanRandomized controlled trialEfficacy outcome
In each baseline BMI and HbA1c subgroup, dulaglutide 4.5 mg showed numerically greater weight reduction than 1.5 mg.
In plain wordsIn each starting BMI and HbA1c subgroup, dulaglutide 4.5 mg showed numerically greater weight loss than 1.5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWeight reduction across baseline BMI and HbA1c subgroups
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
4.5 mg once weeklyAs given in this study (human).
Source sentences
Summary
Higher dulaglutide doses were associated with numerically greater weight reduction compared with 1.5 mg in each baseline BMI and HbA1c subgroup.
1 context sentence(design, population, supporting numbers)
Summary · context
To evaluate the impact of dulaglutide 3.0 and 4.5 mg versus 1.5 mg on body weight in patients with type 2 diabetes (T2D) based on exploratory analyses of the AWARD-11 trial.Materials and methodsPatients were randomized to once-weekly dulaglutide 1.5 (n = 612), 3.0 (n = 616) or 4.5 mg (n = 614) for 52 weeks.
Report a problemFND-3418984105

Studies that did not test the peptide alone3

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In dulaglutide-treated patients with type II diabetes, absolute weight reduction increased with baseline BMI category.
In plain wordsIn patients with diabetes receiving dulaglutide, higher starting BMI categories showed greater absolute weight loss than lower categories.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseAbsolute weight reduction by baseline BMI
Study
n: not reported in source
Comparator
Lower BMI categories
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Absolute weight reduction increased with increasing BMI category, but percentage weight loss was similar between subgroups.
1 context sentence(design, population, supporting numbers)
Summary · context
To evaluate the impact of dulaglutide 3.0 and 4.5 mg versus 1.5 mg on body weight in patients with type 2 diabetes (T2D) based on exploratory analyses of the AWARD-11 trial.Materials and methodsPatients were randomized to once-weekly dulaglutide 1.5 (n = 612), 3.0 (n = 616) or 4.5 mg (n = 614) for 52 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3418984106
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In dulaglutide-treated patients with type II diabetes, percentage weight loss was similar between baseline BMI subgroups.
In plain wordsIn patients with diabetes receiving dulaglutide, percentage weight loss was similar between starting BMI subgroups.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changePercentage weight loss by baseline BMI
Study
n: not reported in source
Comparator
Baseline BMI subgroups
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Absolute weight reduction increased with increasing BMI category, but percentage weight loss was similar between subgroups.
1 context sentence(design, population, supporting numbers)
Summary · context
To evaluate the impact of dulaglutide 3.0 and 4.5 mg versus 1.5 mg on body weight in patients with type 2 diabetes (T2D) based on exploratory analyses of the AWARD-11 trial.Materials and methodsPatients were randomized to once-weekly dulaglutide 1.5 (n = 612), 3.0 (n = 616) or 4.5 mg (n = 614) for 52 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3418984107
08HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In dulaglutide-treated patients with type II diabetes, weight reductions were greater with lower than higher baseline HbA1c.
In plain wordsIn patients with diabetes receiving dulaglutide, lower starting HbA1c was linked to greater weight loss than higher starting HbA1c.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseWeight reduction by baseline HbA1c
Study
n: not reported in source
Comparator
Higher baseline HbA1c
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Weight reductions with dulaglutide were greater in patients with lower versus higher baseline HbA1c.
1 context sentence(design, population, supporting numbers)
Summary · context
To evaluate the impact of dulaglutide 3.0 and 4.5 mg versus 1.5 mg on body weight in patients with type 2 diabetes (T2D) based on exploratory analyses of the AWARD-11 trial.Materials and methodsPatients were randomized to once-weekly dulaglutide 1.5 (n = 612), 3.0 (n = 616) or 4.5 mg (n = 614) for 52 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3418984108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.